IGLV4-3: The Potential Drug Target and Biomarker for Treatment of Inflammatory Neuropathies

Target Name: IGLV4-3

NCBI ID: G28786

IGLV4-3

Other Name(s): Immunoglobulin lambda variable 4-3 | V5-1 | IGLV43 | immunoglobulin lambda variable 4-3

IGLV4-3: The Potential Drug Target and Biomarker for Treatment of Inflammatory Neuropathies

The immune system is a crucial part of our bodies, and it plays a vital role in protecting our body from external threats such as viruses, bacteria, and diseases. However, when the immune system becomes imbalanced or malfunctioning, it can cause a range of inflammatory neuropathies that can significantly impact our quality of life. One of the most common forms of inflammatory neuropathies is multiple sclerosis (MS), which is a progressive disease that can cause muscle weakness, fatigue, and vision loss.

Multiple sclerosis is an autoimmune disorder that affects the central nervous system, and it is characterized by the immune system attacking the protective covering of nerve fibers, known as myelin. The immune system mistakenly attacks the myelin sheath, leading to the displacement of nerve signals, which can cause a range of symptoms such as muscle weakness, fatigue, and vision loss.

IGLV4-3: A Potential Drug Target

IGLV4-3 is a protein that is expressed in the immune system and has been shown to play a role in the development and progression of multiple sclerosis. The IGLV4-3 protein is a member of the immunoglobulin lambda variable family, which is a subclass of antibodies that play a critical role in the immune response.

IGLV4-3 has been shown to interact with several different molecules, including the cytokine interferon-gamma (IFN-纬) and the chemokine signal regulatory protein (CSRP). CSRP is a protein that is expressed in many different tissues and has been shown to play a role in the regulation of immune responses. IGLV4-3 has been shown to bind to CSRP and to inhibit its activity, which could potentially lead to an imbalance in the immune response.

Drug Development

The potential use of IGLV4-3 as a drug target for the treatment of inflammatory neuropathies such as MS is an exciting area of research. Studies have shown that IGLV4-3 has the potential to slow down or stop the progression of MS, and to improve the immune response against the disease.

One of the main advantages of IGLV4-3 as a drug target is its ability to modulate the immune response without affecting the overall immune system. This is because IGLV4-3 is primarily expressed in the immune system and does not have a significant impact on other parts of the body. This makes it a potential candidate for a drug that can be used to treat MS without causing unintended side effects.

Another advantage of IGLV4-3 is its ability to target a specific protein, which makes it a more efficient and effective drug target than many other proteins. This is because drugs that target a specific protein are more likely to have a more targeted and effective response than drugs that target multiple proteins.

Conclusion

IGLV4-3 is a protein that has been shown to play a role in the development and progression of multiple sclerosis. It is also a potential drug target that has the potential to slow down or stop the progression of MS and to improve the immune response against the disease. Further research is needed to fully understand the potential of IGLV4-3 as a drug target for the treatment of inflammatory neuropathies.

Protein Name: Immunoglobulin Lambda Variable 4-3

Functions: V region of the variable domain of immunoglobulin light chains that participates in the antigen recognition (PubMed:24600447). Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:20176268, PubMed:22158414). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:17576170, PubMed:20176268)

The "IGLV4-3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGLV4-3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets